Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Lynk Doses First Cohort of Psoriasis Patients with Topical Third-Gen JAK Inhibitor

publication date: May 25, 2023

Hangzhou Lynk Pharma has dosed the first cohort of psoriatic patients in a China Phase Ib clinical trial of LNK01004 ointment, a topical third-gen, pan-JAK inhibitor that is aimed at psoriasis and other related conditions. Because the drug is topical, it is expected to have minimal systemic exposure and should avoid potential safety issues. The trial enrolled China patients with mild to moderate plaque psoriasis. Lynk has also started trials of LNK01003, another third-gen JAK inhibitor. It is aimed at ulcerative colitis and concentrates exposure of the oral drug to the gastrointestinal tract, again avoiding systemic immunosuppression. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China